GENOMIC EXPRESSION APS

Their core work

Danish biotech SME developing non-invasive liquid biopsy technology for bladder cancer detection and recurrence monitoring. Their core product is a urine-based cancer cell filtration device that captures tumour cells from urine, then analyses their DNA and RNA — replacing the painful, expensive cystoscopy procedure currently used to monitor bladder cancer patients. The work targets a clear clinical and economic problem: bladder cancer has the highest lifetime treatment cost of any cancer because patients require repeated invasive check-ups for life. Genomic Expression's platform aims to cut those costs roughly in half while improving patient quality of life.

What they specialise in

How they've shifted over time

In 2015 the company used a Phase 1 SME grant (BLACANDI, EUR 50,000) to test the business and clinical feasibility of cutting bladder cancer management costs. By 2017 they had won a much larger Phase 2 SME contract (OneRNA4Bladder, EUR 3.7M) to actually build and validate the urine cell filtration device with DNA/RNA readout. The trajectory is a textbook EU SME instrument progression — feasibility study to full product development — all on the same single clinical target.

After OneRNA4Bladder ended in 2020, the natural next step is clinical validation, regulatory approval (CE-IVD / FDA) and commercial launch — partners interested in bladder cancer screening, urology trials, or in-vitro diagnostics distribution would be the relevant collaborators.

How they like to work

Genomic Expression coordinated both of its H2020 projects, but the dataset records zero consortium partners — consistent with the SME instrument, which is typically a single-beneficiary scheme. They behave as an independent product-development company that uses EU funding to advance their own diagnostic platform rather than as a network builder. Anyone working with them is likely engaging directly with the company, not joining a wider research consortium.

No formal H2020 consortium partners are recorded, since both grants were single-beneficiary SME instruments coordinated solely by Genomic Expression from Copenhagen, Denmark.

What sets them apart

Genomic Expression is unusual in being a focused single-product SME: nearly EUR 3.8M of EU money has gone into one clinical problem — non-invasive bladder cancer monitoring via urine — rather than a portfolio of platforms. That focus makes them a credible technology partner for urology clinics, IVD manufacturers and oncology networks looking specifically for a cystoscopy alternative, but it also means they are not a general-purpose oncology diagnostics shop. Their strength is depth on one disease, not breadth.

Highlights from their portfolio

• OneRNA4Bladder
  EUR 3.7M Phase 2 SME grant — the company's flagship and the project that turned the BLACANDI concept into an actual urine-based cell capture and DNA/RNA analysis platform.
• BLACANDI
  The 2015 Phase 1 feasibility study that defined the cost-reduction value proposition (halving bladder cancer management costs) later built into OneRNA4Bladder.